Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan may spot hidden heart infections

NCT ID NCT03695861

Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special PET-CT scan using a radioactive tracer (18F-FDG) can improve diagnosis of infectious endocarditis on natural heart valves. Researchers scanned 31 adults with suspected endocarditis within 5 days of starting care. The goal was to see how well the scan detects the infection and any spread to other parts of the body, compared to standard criteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG (a radioactive tracer used in PET-CT scans)
What this could lead to
If successful, this could make it easier and faster to diagnose heart valve infections on natural valves, helping doctors start the right treatment sooner.
What could go wrong
This is a small, completed study (31 people) looking at diagnostic accuracy, not a treatment trial. The scan may not always catch the infection, and results need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

31 people

The number who actually took part.

Started

Nov 2018

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any patient ≥ 18 years treated at the university hospital center of Bordeaux for suspicion of infectious endocarditis on a native valve with a "definite" or "possible" diagnosis according to the ESC 2015 modified diagnostic criteria, agreeing to participate, * Affiliated person or beneficiary of a social security scheme, * Free, informed and written consent (no later than the day of inclusion and before any exam required by the research). Exclusion Criteria: * Patient with a vital failure (haemodynamic, respiratory or neurological instability), requiring treatment in the intensive care unit and / or urgent surgery incompatible with performing PET-CT, * Pregnant or nursing woman, * Patient who has already been treated for infective endocarditis within six months of enrollment, * Patient who had cardiac surgery in the two months preceding inclusion, * Patient who has previously been hypersensitive to fluorodeoxyglucose and / or excipients of the radiotracer, * Patient unable to sign consent, * Patient under legal protection, * Women of childbearing age who do not benefit from effective contraception (HAS criteria), * Patient in a period of relative exclusion from another research protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endocarditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocarditis infective endocarditis subacute bacterial endocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endocarditis

Contacts and locations

Locations

  • University hospital, Bordeaux

    Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.